- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02769234
EEG/ERP Longitudinal Study in Alzheimer's Disease (AD)
ERP and qEEG Measures Collected in Outpatient Settings as Indices of Disease Progression in Alzheimer's Disease (AD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In study NCT00582127, two age-matched cohorts (mild AD, n=98 and healthy controls, n=100) were recruited to 7 clinical sites to undergo a broad range of clinical, neuropsychological, and neuroelectrophysiological tests. The complete battery of ADNI neuropsychological tests were performed on the mild AD subjects as well as standard blood tests and MRI using the ADNI protocol. MRI volumetry analysis was performed on the MRI data. Both cohorts underwent a 3-minute EEG recording and event-related potential (ERP) testing using a standard 2-deviant auditory oddball paradigm with the COGNISION(tm) System from Neuronetrix. The study showed that specific EEG/ERP features could be used to discriminate the mild AD cohort from healthy controls.
The current study is intended as a follow up to NCT00582127.AD subjects that successfully completed COGNISION™ and psychometric testing in the previous study are eligible to be part of the present follow up.
In the first part of the current study, de-identified cognitive and functional data for the AD patients that the sites have collected during regular check ups after testing for the original Neuronetrix study will be shared with the study Sponsor. The retrospective chart review has three main objectives:
- Quantify the rate of cognitive and functional decline in these patients.
- Investigate whether ERP and/or qEEG data collected during testing for the original Neuronetrix study can provide any insight on subsequent rate of cognitive and functional decline.
- Identify study subjects that might still be functional enough to successfully complete a follow-up ERP/qEEG test. These subjects will be offered an opportunity to come back to the sites for follow-up ERP/qEEG and psychometric testing.
Up to 40 subjects will be invited back to the sites. Subjects that choose to enroll in the second part of the study will have an ERP/qEEG test administered by a Neuronetrix certified test administrator. Subjects that complete the test successfully will move on to clinical evaluation and psychometric testing.
Results obtained from this part of the study will be compared with ERP/qEEG and psychometric data from the completed Neuronetrix study mentioned above. The two main objectives of the comparisons will be:
- Investigate whether ERP and qEEG measures collected in outpatient settings show significant changes over time in subjects with AD.
- Correlate longitudinal changes in ERP and qEEG measures (if any) with cognitive and functional decline as measured by psychometric tests.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Florida
-
West Palm Beach, Florida, United States, 33407
- Premiere Research Institute
-
-
Massachusetts
-
Brookline, Massachusetts, United States, 02467
- Boston Center for Memory
-
-
Vermont
-
Bennington, Vermont, United States, 05201
- The Memory Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
Between 60 and 95 years old (inclusive) A diagnosis of Alzheimer's disease A successful ERP/EEG test performed with the COGNISION™ system 2-5 years prior to testing for the current study
A sub-group of up to 40 subjects will be called back to the sites for follow-up ERP/qEEG and psychometric testing. Additional inclusion criteria for these subjects will be:
- Willing and able to undergo ERP/EEG and psychometric testing
- Have a study partner able to provide an independent evaluation of functioning
- Permitted medications stable for at least 2 weeks prior to testing
Exclusion Criteria:
Subjects will not be called back to sites for follow-up testing if they have:
- Known allergy to latex
- Neuropsychological tests administered within three months of study enrollment
- Investigational agents administered within three months of study enrollment
- Severe cognitive and functional deficits that in the judgement of the site PI will prevent them from successfully completing ERP/EEG and/or psychometric testing
- Any significant systemic illness or unstable medical condition at the time of testing which could lead to difficulty complying with the protocol
- Use of psychoactive substances (Gingko Biloba, melatonin, sedatives etc.) will be allowed as long as the subject suspends their use on the day of testing. Smokers will not be required to abstain.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Alzheimer's disease
Subjects with a diagnosis of Alzheimer's disease that successfully performed an ERP/EEG test with the COGNISION(TM) System prior to enrollment for the current study are eligible to participate.
|
The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG.
During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp.
At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting.
The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.
Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation.
Demographic information with also be collected.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlation (longitudinal change) between EEG/ERP vs. Neuropsychological Testing.
Time Frame: 24-60 Months
|
24-60 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlation (longitudinal change) between EEG/ERP vs ADNI-EF composite.
Time Frame: 24-60 Months
|
24-60 Months
|
Correlation (longitudinal change) between EEG/ERP vs. ADNI-Mem composite.
Time Frame: 24-60 Months
|
24-60 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Marco Cecchi, PhD, Neuronetrix, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SRP-1782
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on ERP/EEG test
-
University of Alabama, TuscaloosaUAB Resource Centers for Minority Aging Research (RCMAR)Unknown
-
ERP Biomarker Qualification ConsortiumMerck Sharp & Dohme LLC; Novartis; Takeda; H. Lundbeck A/S; Columbia University; Astellas... and other collaboratorsCompletedSchizophreniaUnited States
-
The University of Hong KongDementias Platform UKUnknownMild Cognitive Impairment | Vascular Dementia | Alzheimer Dementia | Neurocognitive Disorder | Age-related Cognitive DeclineHong Kong
-
Institut National de la Santé Et de la Recherche...Completed
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive Disorder
-
Think Now IncorporatedNational Institute of Mental Health (NIMH); University of California, Berkeley and other collaboratorsCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Mclean HospitalUtah State UniversityCompleted
-
Utah State UniversityUniversity of North Carolina, Chapel Hill; International OCD FoundationCompletedObsessive-Compulsive DisorderUnited States
-
Aarhus University HospitalActive, not recruitingChronic Tic DisorderDenmark